Guide to Ingrezza Medication and Its Common Uses

Ingrezza, also known by its generic name valbenazine, is an oral medication classified as a vesicular monoamine transporter 2 or VMAT2 inhibitor. The United States Food and Drug Administration has approved it for adults with tardive dyskinesia and chorea associated with Huntington disease.

Common Uses of Ingrezza Medication

Tardive dyskinesia is a movement disorder that can develop after exposure to certain medications, particularly some medicines used to treat psychiatric conditions. It may cause repetitive, involuntary movements involving the face, tongue, trunk, arms, or legs. Ingrezza is used to help manage these movements in adults with tardive dyskinesia.

Ingrezza is also approved for adults experiencing chorea associated with Huntington disease. Chorea involves irregular and unpredictable movements that can occur as part of this inherited neurological disorder. The medication works by inhibiting VMAT2, a protein involved in transporting monoamines within nerve cells.

Common considerations include:

• Ingrezza is available as capsules and as Ingrezza Sprinkle capsules.
• It can generally be taken with or without food.
• The recommended dosage depends on the condition being treated and individual factors.
• Dose adjustments may be needed for certain liver conditions or medication interactions.
• Treatment should be taken according to the prescribing healthcare professional's instructions.

Important Safety Information and Possible Side Effects

Like other prescription medicines, Ingrezza can cause side effects and may not be appropriate for everyone. Somnolence, meaning sleepiness, is the most common adverse reaction identified in adults treated for tardive dyskinesia. In people treated for Huntington disease chorea, reported common adverse reactions include sleepiness, lethargy or sedation, hives, rash, and insomnia.

The prescribing information also contains important warnings and precautions. In people with Huntington disease, Ingrezza carries a boxed warning concerning depression and suicidal thoughts or behavior. Patients, caregivers, and families should promptly discuss concerning changes in mood or behavior with a healthcare professional. The medication may also cause QT interval prolongation, hypersensitivity reactions, sedation, and Parkinson-like symptoms in some patients.

Important points include:

• Tell a healthcare professional about all prescription medicines, over-the-counter medicines, and supplements being taken.
• Certain CYP3A4 and CYP2D6 medicines can require dosage adjustments.
• MAO inhibitors should not be used together with Ingrezza.
• People with certain heart rhythm conditions may require special consideration.
• Patients should avoid driving or operating hazardous machinery if the medication causes significant sleepiness or sedation.

Ingrezza is a prescription medication intended for specific movement disorders. Its appropriate use, dosage, and monitoring should be determined by a qualified healthcare professional based on the individual's medical history and other medications. This information is provided for educational purposes only and is not intended as medical advice, diagnosis, treatment, sales, or healthcare services.